• Publications
  • Influence
International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors.
Experiments with receptor antagonists and mice with targeted disruption of adenosine A(1), A(2A), and A(3) expression reveal roles for these receptors under physiological and particularly pathophysiological conditions.
International Union of Pharmacology LVIII: Update on the P2Y G Protein-Coupled Nucleotide Receptors: From Molecular Mechanisms and Pathophysiology to Therapy
There have been many advances in our knowledge about different aspects of P2Y receptor signaling since the last review published by our International Union of Pharmacology subcommittee. More receptor
Adenosine receptors as therapeutic targets
Recent advances in the understanding of the roles of the various adenosine receptor subtypes, and in the development of selective and potent ligands, have brought the goal of therapeutic application of adenosines receptor modulators considerably closer.
Structure of an Agonist-Bound Human A2A Adenosine Receptor
The molecule UK-432097 is defined as a “conformationally selective agonist” capable of receptor stabilization in a specific active-state configuration and sheds light on G protein–coupled receptor activation.
International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of Adenosine Receptors—An Update
In the 10 years since our previous International Union of Basic and Clinical Pharmacology report on the nomenclature and classification of adenosine receptors, no developments have led to major
UDP acting at P2Y6 receptors is a mediator of microglial phagocytosis
The P2Y6 receptor is upregulated when neurons are damaged, and could function as a sensor for phagocytosis by sensing diffusible UDP signals, which is a previously unknown pathophysiological function of P2 receptors in microglia.
Characterization of the UDP-glucose receptor (re-named here the P2Y14 receptor) adds diversity to the P2Y receptor family.
The cloning of a human G-protein-coupled receptor (GPCR) that specifically responds to UDP-glucose and related sugar-nucleotides has been reported recently. This receptor has important structural
Purine and pyrimidine (P2) receptors as drug targets.
Competitive and selective antagonism of P2Y1 receptors by N6‐methyl 2′‐deoxyadenosine 3′,5′‐bisphosphate
The antagonist activity of N6‐methyl 2′‐deoxyadenosine 3′,5′‐bisphosphate (N6MABP) has been examined at the phospholipase C‐coupled P2Y1 receptor of turkey erythrocyte membranes. N6MABP antagonized
Adenosine A3 receptors: novel ligands and paradoxical effects.
  • K. Jacobson
  • Medicine, Chemistry
    Trends in pharmacological sciences
  • 1 May 1998
How A3 receptor agonists might be useful in treating inflammatory conditions, possibly through their inhibition of tumour necrosis factor alpha (TNF-alpha) release, which has been shown in macrophages is described.